Genmab Conference Call Summary Company Overview - **Company**: Genmab (NasdaqGS: GMAB) - **Year**: 2025 was highlighted as a strong year for Genmab, with significant financial growth and advancements in their late-stage pipeline, including three key programs: EPKINLY, Rina-S, and pivekimab [3][4] Financial Performance - **Revenue Growth**: Strong revenue growth was reported, alongside disciplined operational expenditure management, leading to profit flowing to the bottom line [3] - **Pipeline Progress**: The company has three late-stage programs with meaningful clinical data expected to support potential launches in 2027 [4] Key Programs and Commercial Opportunities EPKINLY - **Market Potential**: EPKINLY is viewed as a blockbuster medicine with a potential market opportunity exceeding $3 billion [6] - **Therapeutic Indications**: The program is expanding into earlier lines of therapy, particularly in second-line follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) [6][8] - **Clinical Data**: Positive performance in initial phases and robust uptake in community settings were noted [8][27] - **Regulatory Timeline**: Expected readouts for frontline DLBCL and second-line DLBCL trials in 2026, with potential regulatory submissions leading to a launch in 2027 [15][16] Rina-S - **Market Potential**: Rina-S has a peak opportunity estimated at over $2 billion, targeting multiple subsegments in gynecologic oncology [9][10] - **Clinical Trials**: Three ongoing phase 3 trials are in progress, with the first registrational readout expected in 2026 [9][10] - **Differentiation**: The program is positioned as potentially best-in-class with differentiated efficacy and safety profiles, allowing for longer durations of therapy [34][35] Pivekimab - **Market Potential**: Pivekimab is also projected to be a multi-billion dollar opportunity, with two ongoing phase 3 trials in head and neck cancer [11][12] - **Regulatory Timeline**: Expected readouts for these trials in 2026, with a potential launch in 2027 [11][12] Commercialization Strategy - **Market Readiness**: Genmab has been building its commercial infrastructure in the U.S., Japan, and Europe, preparing for the launches of Rina-S and pivekimab [18][22] - **Track Record**: The company has successfully launched TIVDAK and EPKINLY, which provides confidence for future launches [24][22] Competitive Landscape - **EPKINLY vs. Competitors**: EPKINLY is positioned to penetrate earlier lines of treatment and gain market share against other CD20 bispecific therapies [25][26] - **Rina-S Differentiation**: Rina-S is expected to outperform existing ADCs in ovarian cancer due to its efficacy across various folate receptor alpha expression levels [34][35] Milestones and Catalysts for 2026 - **Key Readouts**: Two phase 3 readouts for EPKINLY in DLBCL, and the first registrational data for Rina-S and pivekimab are anticipated in 2026, leading to potential launches in 2027 [52][54] - **Focus on Deleveraging**: The company aims to reduce its debt from the acquisition of Merus, targeting a gross leverage ratio of three times or below by the end of 2027 [50][51] Conclusion - Genmab is positioned for significant growth with multiple late-stage programs expected to yield positive clinical data and commercial opportunities in the coming years. The company’s strategic focus on commercialization and market readiness, alongside a strong pipeline, sets a promising outlook for future performance [4][12][54]